SUPLEXA cell therapy - Alloplex Biotherapeutics
Alternative Names: SUPLEXA Therapeutic CellsLatest Information Update: 13 Aug 2024
At a glance
- Originator Alloplex Biotherapeutics
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Haematological malignancies; Solid tumours
Most Recent Events
- 23 Jul 2024 Alloplex Biotherapeutics completes a phase I trial in Haematological malignancies and Solid tumours (Late-stage disease; Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in Australia (IV) (NCT05237206)
- 31 May 2024 Adverse events and efficacy data from Phase-I trial in Haematological malignancies presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 22 Aug 2023 SUPLEXA cell therapy - Alloplex Biotherapeutics is available for licensing as of 22 Aug 2023. https://alloplexbio.com/